Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

313
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
313
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

60
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
60
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

101
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
101
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

39
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
39
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

56
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
56
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

338
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
338

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a self-questionnaire (APP-Chutes®) for pre-screening older persons at moderate or high risk of falling according to the World Falls Guidelines.

Geriatrie et psychologie neuropsychiatrie du vieillissement·2026
Same author

[Edgar Morin and Complexity: The Inspiration Behind the Specifications Framework for the Gerontopoles of the French Union of Gerontopoles].

Geriatrie et psychologie neuropsychiatrie du vieillissement·2026
Same author

Allergic rhinitis in the elderly. In collaboration with ARIA guidelines.

The journal of allergy and clinical immunology. In practice·2026
Same author

CGM-based metrics and mortality in older adults living with type 2 diabetes on insulin therapy: a secondary analysis of the HYPOAGE study.

Diabetes & metabolism·2026
Same author

Effect of home-based rehabilitation in frail older adults after cardiac surgery: a prospective feasibility study.

Journal of rehabilitation medicine·2026
Same author

Assessment of the "world guidelines for falls prevention and management" algorithm in older volunteers.

Aging clinical and experimental research·2026

Related Experiment Video

Updated: Nov 1, 2025

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

12.8K

[Empagliflozin in the elderly].

Gilles Berrut1, Anne Sophie Boureau2, Jean Noel Trochu3

  • 1Pôle hospitalo-universitaire de gérontologie clinique, CHU de Nantes, France, Université de Nantes, Faculté de médecine, Nantes, France.

Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement
|June 24, 2021
PubMed
Summary
This summary is machine-generated.

Gliflozins, a novel drug class, lower blood glucose by inhibiting renal glucose reabsorption, leading to weight loss and improved HbA1c. Empagliflozin also reduces mortality and offers kidney protection in type 2 diabetes.

Keywords:
chronic kidney diseasediabetes mellituselderlygliflozinesheart failure

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

544
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

476

Related Experiment Videos

Last Updated: Nov 1, 2025

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

12.8K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

544
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

476

Area of Science:

  • Pharmacology
  • Nephrology
  • Endocrinology

Background:

  • Gliflozins represent a new therapeutic class targeting glucose and sodium reabsorption.
  • Their mechanism involves inhibiting the SGLT co-transporter in the renal proximal tubule.

Purpose of the Study:

  • To summarize the therapeutic benefits and applications of gliflozins.
  • To highlight the role of empagliflozin in managing type 2 diabetes and related complications.

Main Methods:

  • Review of gliflozin's mechanism of action.
  • Analysis of clinical outcomes, including HbA1c, weight loss, and cardiovascular/renal protection.

Main Results:

  • Gliflozins reduce blood glucose, cause glycosuria, and promote weight loss (2-3 kg).
  • They improve HbA1c by approximately 0.7% and lower blood pressure.
  • Empagliflozin demonstrated reduced all-cause mortality, cardiac decompensation, and nephroprotection.

Conclusions:

  • Gliflozins are effective in managing type 2 diabetes without directly stimulating insulin secretion, thus not causing hypoglycemia.
  • Their benefits extend to cardiovascular and renal protection, making them valuable for elderly patients with multiple comorbidities.
  • The use of gliflozins is expected to expand to various chronic diseases.